Table 2—

Profile of tuberculosis(TB) cases according to vital status, and results of bivariate and multivariable analysis in the European Union (EU) during 2002–2004

VariablePatients who diedPatients who did not dieTotal subjects nBivariate crude OR (95% CI)Multivariable adjusted OR (95% CI)
Total#3085 (7.8)36481 (92.2)39566
Year of notification
 2002845 (8.0)9684 (92.0)1052911
 20031159 (8.1)13216 (91.9)143751.01 (0.92–1.10)##1.02 (0.92–1.13)##
 20041081 (7.4)13581 (92.6)146620.91 (0.83–1.00)##0.93 (0.84–1.03)##
Sex
 Female835 (6.0)13007 (94.0)1384211
 Male2250 (8.7)23474 (91.3)257241.49 (1.38–1.62)***1.48 (1.35–1.61)***
Age group yrs
 0–1923 (1.1)2133 (98.9)215611
 20–39327 (2.2)14864 (97.8)151912.04 (1.33–3.12)***1.88 (1.23–2.88)***
 40–59891 (7.1)11714 (92.9)12,6057.05 (4.64–10.72)***5.18 (3.40–7.88)***
 60+1844 (19.2)7770 (80.8)961422.01 (14.43–33.56)***18.40 (12.12–27.92)***
Geographical origin
 Europe2650 (9.9)24086 (90.1)2673611
 Balkans+71 (3.9)1772 (96.1)18430.36 (0.29–0.46)***0.46 (0.36–0.59)***
 FSU118 (5.9)1878 (94.1)19960.57 (0.47–0.69)***0.50 (0.41–0.61)***
 Indian subcontinent§93 (3.8)2332 (96.2)24250.36 (0.29–0.45)***0.61 (0.48–0.77)***
 Rest of Asiaƒ34 (2.2)1538 (97.8)15720.20 (0.14–0.28)***0.43 (0.30–0.61)***
 Africa99 (2.2)4460 (97.8)45590.20 (0.16–0.25)***0.55 (0.44–0.68)***
 America and Oceania20 (4.6)415 (95.4)4350.44 (0.28–0.69)***0.77 (0.48–1.24)##
Site of disease
 Extrapulmonary alone332 (5.3)5940 (94.7)627211
 Pulmonary2753 (8.3)30541 (91.7)332941.61 (1.43–1.81)***1.42 (1.25–1.61)***
Previous history of TB¶¶
 No2400 (7.0)31697 (93.0)340971Not included¶¶
 Yes685 (12.5)4784 (87.5)54691.89 (1.73–2.07)***
MDR testing results¶¶
 Not MDR2759 (7.4)34753 (92.6)3751211
 Primary MDR106 (11.2)842 (88.8)9481.59 (1.29–1.95)***2.49 (1.98–3.12)***
 Secondary MDR220 (19.9)886 (80.1)11063.13 (2.68–3.65)***3.61 (3.02–4.32)***
Country of notification
 Austria180 (9.4)1725 (90.6)19052.00 (1.54–2.59)***1.25 (0.95–1.64)##
 Belgium137 (7.0)1808 (93.0)19451.45 (1.10–1.90)***0.92 (0.70–1.23)##
 Czech Republic93 (5.7)1536 (94.3)16291.16 (0.86–1.56)##0.47 (0.35–0.64)***
 Denmark58 (6.6)827 (93.4)8851.34 (0.96–1.88)##1.31 (0.92–1.88)##
 Estonia145 (10.0)1301 (90.0)14462.13 (1.63–2.80)***1.12 (0.84–1.50)##
 Germany912 (9.6)8626 (90.4)95382.02 (1.62–2.52)***1.19 (0.95–1.51)##
 Ireland38 (6.1)580 (93.9)6181.25 (0.85–1.85)##0.83 (0.55–1.24)##
 Latvia256 (7.2)3277 (92.8)35331.49 (1.17–1.91)***0.85 (0.66–1.11)##
 Lithuania341 (11.4)2649 (88.6)29902.46 (1.94–3.13)***1.11 (0.85–1.44)##
 The Netherlands93 (5.0)1779 (95.0)187211
 Portugal208 (4.7)4,215 (95.3)44230.94 (0.73–1.21)##0.66 (0.51–0.86)***
 Slovakia151 (12.1)1095 (87.9)12462.64 (2.01–3.46)***1.08 (0.81–1.43)##
 Slovenia90 (11.6)689 (88.4)7792.50 (1.84–3.39)***1.22 (0.89–1.68)##
 Sweden51 (7.3)648 (92.7)6991.51 (1.06–2.14)*1.18 (0.81–1.71)##
 UK332 (5.5)5726 (94.5)60581.11 (0.88–1.40)##1.22 (0.95–1.58)##
  • Data are presented as n (%), unless otherwise indicated. OR: odds ratio; CI: confidence interval; FSU, Former Soviet Union countries (Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova Republic, Russian Federation, Tajikistan, Turkmenistan, Ukraine, Uzbekistan); MDR: multidrug resistance (resistance to at least isoniazid and rifampicin). #: including all culture-positive cases with results on initial susceptibility testing to isoniazid and rifampicin, and excluding cases with missing data on age, sex, country of origin and site of disease. : EU and other non-EU countries including Baltic States (Estonia, Latvia, Lithuania); +: Albania, Bosnia and Herzegovina, Croatia, Macedonia FYR, Montenegro, Serbia, Turkey; §: Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka; ƒ: excluding Turkey and Asian FSU countries; ##: nonsignificant; ¶¶: interaction between previous history of TB and MDR was taken into account by recoding MDR status in not MDR, primary MDR (without previous history of TB) and secondary MDR (with previous history). * p<0.05; ***: p<0.001.